State of the art and future directions in nanomedicine for tuberculosis.

Show simple item record

dc.contributor.author Dube, Admire
dc.contributor.author Lemmer, Yolandy
dc.contributor.author Hayeshi, Rose
dc.contributor.author Balogun, Mohammed
dc.contributor.author Labuschagne, Philip
dc.contributor.author Swai, H.
dc.contributor.author Kalombo, Lonji
dc.date.accessioned 2019-10-16T07:55:38Z
dc.date.available 2019-10-16T07:55:38Z
dc.date.issued 2013-12-01
dc.identifier.other 24102208
dc.identifier.uri https://doi.org/10.1517/17425247.2014.846905
dc.identifier.uri http://dspace.nm-aist.ac.tz/handle/123456789/490
dc.description Research Article published by Expert Opinion on Drug Delivery Volume 10, Issue 1220 -13 en_US
dc.description.abstract Introduction: Tuberculosis (TB) ranks the second leading cause of death from an infectious disease worldwide. However, treatment of TB is affected by poor patient compliance due to the requirement for daily drug administration, for lengthy periods of time, often with severe drug-induced side effects. Nanomedicines have the potential to improve treatment outcomes by providing therapies with reduced drug doses, administered less frequently, under shortened treatment durations. Areas covered: In this article, we present the pathophysiology of the disease, focusing on pulmonary TB and the characteristics of drugs used in treatment and discuss the application of nanomedicines within this scope. We also discuss new formulation approaches for TB nanomedicines and directions for future research. Expert opinion: Nanomedicines have the potential to improve TB treatment outcomes. New approaches such as nanoparticle systems able to impact the immune response of macrophages and deliver drug intracellularly, as well as the use of polymer–drug conjugates for drug delivery, are likely to play an important role in TB nanomedicines in future. However, further research is required before TB nanomedicines can be translated to the clinic. en_US
dc.language.iso en en_US
dc.publisher Expert Opinion on Drug Delivery en_US
dc.subject multimodal nanoparticles en_US
dc.subject polymer–drug conjugates en_US
dc.subject targeted drug delivery en_US
dc.title State of the art and future directions in nanomedicine for tuberculosis. en_US
dc.type Article en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search Our NM-AIST IR


My NM-AIST IR Account